

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1247	(514/303,546/118).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:34
L2	353	I1 and imidazo	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:34
L3	198	I2 and pyridin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35
L4	194	I3 and NO	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35
L5	26	I4 and synthase	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/10/12 07:35

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	24	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:37:29 ON 12 OCT 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:37:34 ON 12 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10573203.str



chain nodes :  
 10 11 18 19 21 22 23 24 25 26 28  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 12 13 14 15 16 17  
 chain bonds :  
 8-10 9-19 10-11 10-26 11-12 11-21 11-22 13-25 14-18 15-24 16-23 18-28  
 ring bonds :  
 1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 7-8 8-9 12-13 12-17 13-14 14-15 15-16  
 16-17  
 exact/norm bonds :  
 3-7 4-9 7-8 8-9 10-26 14-18 18-28  
 exact bonds :  
 8-10 9-19 10-11 11-12 11-21 11-22 13-25 15-24 16-23  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17  
 isolated ring systems :  
 containing 1 : 12 :

G1:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:37:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 44 TO 476

PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:37:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 256 TO ITERATE

100.0% PROCESSED 256 ITERATIONS

133 ANSWERS

SEARCH TIME: 00.00.01

L3 133 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 07:38:01 ON 12 OCT 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Oct 2007 VOL 147 ISS 17  
FILE LAST UPDATED: 11 Oct 2007 (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:341554 CAPLUS

DOCUMENT NUMBER: 144:381708

TITLE: In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase

AUTHOR(S): Lehner, Martin D.; Marx, Degenhard; Boer, Rainer; Strub, Andreas; Hesslinger, Christian; Eltze, Manfred; Ulrich, Wolf-Ruediger; Schwoebel, Frank; Schermuly, Ralph Theo; Barsig, Johannes

CORPORATE SOURCE: Department of Pharmacology, ALTANA Pharma AG, Konstanz, Germany

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2006), 317(1), 181-187

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Excessive release of nitric oxide from inducible nitric-oxide synthase (iNOS) has been postulated to contribute to pathol. in a number of inflammatory diseases. We recently identified imidazopyridine derivs. as a novel class of potent nitric-oxide synthase inhibitors with high selectivity for the inducible isoform. In the present study, we tested the in vivo potency of BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a selected member of this inhibitor class, in three different rat models of lipopolysaccharide-induced systemic inflammation. Delayed administration of BYK191023 dose-dependently suppressed the lipopolysaccharide-induced increase in plasma nitrate/nitrite (NOx) levels with an ED50 of 14.9 µmol/kg/h. In a model of systemic hypotension following high-dose lipopolysaccharide challenge, curative administration of BYK191023 at a dose that inhibited 83% of the NOx increase completely prevented the gradual decrease in mean


arterial blood pressure observed in vehicle-treated control animals. The vasopressor effect was specific for endotoxemic animals since BYK191023 did not affect blood pressure in saline-challenged controls. In addition, in a model of lipopolysaccharide-induced vascular hyporesponsiveness, BYK191023 infusion partially restored normal blood pressure responses to norepinephrine and sodium nitroprusside via an L-arginine competitive mechanism. Taken together, BYK191023 is a member of a novel class of highly isoform-selective iNOS inhibitors with promising in vivo activity suitable for mechanistic studies on the role of selective iNOS inhibition as well as clin. development.

IT 608880-48-4, BYK191023

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(in vivo characterization of inducible nitric-oxide synthase inhibitor imidazopyridine BYK191023)

RN 608880-48-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:43156 CAPLUS

DOCUMENT NUMBER: 144:163527

TITLE: The novel imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase

AUTHOR(S): Strub, Andreas; Ulrich, Wolf-Ruediger; Hesslinger, Christian; Eltze, Manfred; Fuchss, Thomas; Strassner, Jochen; Strand, Susanne; Lehner, Martin D.; Boer, Rainer

CORPORATE SOURCE: Departments of Biochemistry, Chemistry and Pharmacology, ALTANA Pharma AG, Konstanz, Germany

SOURCE: Molecular Pharmacology (2006), 69(1), 328-337  
CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics


DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have identified imidazopyridine derivs. as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 µM, and 162 µM, resp. Inhibition of inducible NO synthase was competitive with L-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance expts., BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 µM, and >500 µM, resp. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher L-arginine concns. in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines

up to high micromolar concns. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC<sub>50</sub> = 7 µM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC<sub>50</sub> > 100 µM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC<sub>50</sub> > 100 µM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new highly selective iNOS inhibitor structurally unrelated to known compds. and L-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.

IT 608880-48-4, BYK 191023  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (structure activity relationship studied of imidazopyridine compds. as selective inhibitors of nitric-oxide synthase isoforms)  
 RN 608880-48-4 CAPLUS  
 CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300447 CAPLUS

DOCUMENT NUMBER: 142:373838

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276015	A1	20050407	AU 2004-276015	20040930
CA 2540083	A1	20050407	CA 2004-2540083	20040930
EP 1675854	A1	20060705	EP 2004-787263	20040930





R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1856491	A	20061101	CN 2004-80027592	20040930
BR 2004014972	A	20061107	BR 2004-14972	20040930
JP 2007507467	T	20070329	JP 2006-530264	20040930
NO 2006001344	A	20060324	NO 2006-1344	20060324
MX 2006PA03349	A	20060608	MX 2006-PA3349	20060324
US 2007043073	A1	20070222	US 2006-573484	20060324
IN 2006MN00475	A	20070316	IN 2006-MN475	20060424


PRIORITY APPLN. INFO.: EP 2003-22053 A 20031001  
 WO 2004-EP52378 W 20040930

OTHER SOURCE(S): CASREACT 142:373838; MARPAT 142:373838  
 GI




- AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.
- IT 849357-47-7P 849357-48-8P 849357-49-9P  
 849357-50-2P 849357-51-3P 849357-52-4P  
 849357-54-6P 849357-55-7P 849357-56-8P  
 849357-57-9P 849357-58-0P 849357-59-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors).
- RN 849357-47-7 CAPLUS
- CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-

b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 849357-48-8 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849357-49-9 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849357-50-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849357-51-3 CAPLUS

CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849357-52-4 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 849357-54-6 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849357-55-7 CAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849357-56-8 CAPLUS

CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849357-57-9 CAPLUS

CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849357-58-0 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 849357-59-1 CAPLUS

CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




IT 608880-54-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 608880-54-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300446 CAPLUS

DOCUMENT NUMBER: 142:373837

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276014	A1	20050407	AU 2004-276014	20040930
CA 2540243	A1	20050407	CA 2004-2540243	20040930
EP 1670796	A1	20060621	EP 2004-787262	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856495	A	20061101	CN 2004-80027833	20040930
BR 2004014933	A	20061107	BR 2004-14933	20040930
JP 2007507466	T	20070329	JP 2006-530263	20040930
NO 2006001317	A	20060323	NO 2006-1317	20060323
MX 2006PA03351	A	20060608	MX 2006-PA3351	20060324
US 2006293302	A1	20061228	US 2006-573202	20060324
US 7279488	B2	20071009		
IN 2006MN00362	A	20070615	IN 2006-MN362	20060331
PRIORITY APPLN. INFO.:			EP 2003-22046	A 20031001
			WO 2004-EP52377	W 20040930
OTHER SOURCE(S):			CASREACT 142:373837; MARPAT 142:373837	
GI				



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzene-sulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.


IT 849530-66-1P 849530-68-3P 849530-70-7P  
 849530-72-9P 849530-74-1P 849530-76-3P  
 849530-78-5P 849530-80-9P 849530-82-1P  
 849530-84-3P 849530-86-5P 849530-88-7P  
 849530-90-1P 849530-92-3P 849530-94-5P  
 849530-96-7P 849530-98-9P 849531-00-6P  
 849531-02-8P 849531-04-0P 849531-06-2P  
 849531-08-4P 849531-10-8P 849531-12-0P  
 849531-14-2P 849531-16-4P 849531-18-6P  
 849531-20-0P 849531-23-3P 849531-25-5P  
 849531-27-7P 849531-29-9P 849531-31-3P  
 849531-33-5P 849531-36-8P 849531-38-0P  
 849531-40-4P 849531-42-6P 849531-44-8P  
 849531-46-0P 849531-48-2P 849531-50-6P  
 849531-52-8P 849531-54-0P 849531-56-2P  
 849531-58-4P 849531-60-8P 849531-62-0P  
 849531-64-2P 849531-66-4P 849531-68-6P  
 849531-70-0P 849531-72-2P 849531-74-4P  
 849531-76-6P 849531-78-8P 849531-80-2P  
 849531-82-4P 849531-84-6P 849531-86-8P  
 849531-88-0P 849531-90-4P 849531-92-6P  
 849531-94-8P 849531-96-0P 849531-98-2P  
 849532-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)


RN 849530-66-1 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849530-68-3 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 849530-70-7 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 849530-72-9 CAPLUS

CN Piperazine, 1-(4-cyanophenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-74-1 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849530-76-3 CAPLUS

CN Piperazine, 1-(2,4-dimethylphenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 849530-78-5 CAPLUS

CN Piperazine, 1-(3,5-dichlorophenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 849530-80-9 CAPLUS

CN Piperazine, 1-(2-methoxyethyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-82-1 CAPLUS

CN Piperazine, 1-acetyl-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)







RN 849530-84-3 CAPLUS  
 CN Morpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-86-5 CAPLUS  
 CN 1H-1,4-Diazepine, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849530-88-7 CAPLUS  
 CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849530-90-1 CAPLUS  
 CN Piperidine, 4-benzoyl-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-92-3 CAPLUS  
 CN 1,4-Dioxaspiro[4.5]decane, 8-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-94-5 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 849530-96-7 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849530-98-9 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-00-6 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-02-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 849531-04-0 CAPLUS

CN Benzenesulfonamide, N-cyclohexyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-06-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 849531-08-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 849531-10-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N,3-trimethyl- (9CI) (CA INDEX NAME)




RN 849531-12-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 849531-14-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849531-16-4 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-18-6 CAPLUS

CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-20-0 CAPLUS

CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849531-23-3 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 849531-25-5 CAPLUS

CN Piperazine, 1-ethyl-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-27-7 CAPLUS

CN Piperazine, 1-(2,6-dimethylphenyl)-4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 849531-29-9 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849531-31-3 CAPLUS

CN Piperazine, 1-[[3-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-33-5 CAPLUS

CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-36-8 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-2-(trifluoromethoxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-38-0 CAPLUS

CN Isoquinoline, 6,7-diethoxy-1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-40-4 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-2-(trifluoromethyl)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-42-6 CAPLUS

CN Piperazine, 1-[[2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-44-8 CAPLUS

CN Piperazine, 1-[[2-chloro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-46-0 CAPLUS

CN Piperazine, 1-[[3-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 849531-48-2 CAPLUS


CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 849531-50-6 CAPLUS


CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)






RN 849531-52-8 CAPLUS

CN Piperazine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-3-methylphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-54-0 CAPLUS

CN 5H-1,4-Diazepin-5-one, hexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 849531-56-2 CAPLUS

CN 5H-1,4-Diazepin-5-one, 4-ethylhexahydro-1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-58-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849531-60-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 849531-62-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849531-64-2 CAPLUS

CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849531-66-4 CAPLUS

CN Benzenesulfonamide, N-(2-fluoro-4-methylphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-68-6 CAPLUS

CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-70-0 CAPLUS

CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 849531-72-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 849531-74-4 CAPLUS

CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-76-6 CAPLUS

CN Pyrrolidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-78-8 CAPLUS

CN Azetidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-80-2 CAPLUS

CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-82-4 CAPLUS

CN Benzenesulfonamide, N-cyclobutyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-84-6 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 849531-86-8 CAPLUS

CN Pyrrolidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-88-0 CAPLUS

CN Piperidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-90-4 CAPLUS

CN Morpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-92-6 CAPLUS

CN Azetidine, 1-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-94-8 CAPLUS

CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 849531-96-0 CAPLUS

CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-, 1-oxide (9CI) (CA INDEX NAME)




RN 849531-98-2 CAPLUS

CN Thiomorpholine, 4-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 849532-00-9 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 608880-54-2P, 2-[2-[4-Methoxypyridin-2-yl]ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 608880-54-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300445 CAPLUS

DOCUMENT NUMBER: 142:373836

TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors

INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfred; Lehner, Martin; Marx, Degenhard; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030769	A1	20050407	WO 2004-EP52376	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG



AU 2004276013	A1	20050407	AU 2004-276013	20040930
CA 2540242	A1	20050407	CA 2004-2540242	20040930
EP 1673371	A1	20060628	EP 2004-787261	20040930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1856494	A	20061101	CN 2004-80027819	20040930
BR 2004014873	A	20061212	BR 2004-14873	20040930
JP 2007507465	T	20070329	JP 2006-530262	20040930
NO 2006001316	A	20060323	NO 2006-1316	20060323
MX 2006PA03554	A	20060605	MX 2006-PA3554	20060329
IN 2006MN00473	A	20070316	IN 2006-MN473	20060424

PRIORITY APPLN. INFO.: EP 2003-22064 A 20031001  
 WO 2004-EP52376 W 20040930

OTHER SOURCE(S): CASREACT 142:373836; MARPAT 142:373836  
 GI



AB Title compds. I [R1 = alkoxy; A = alkylene; R2 = H, halo, alkyl, alkoxy; Het = (un)substituted monocyclic or fused 5-10 membered (un)saturated heteroaryl containing 1-3 heteroatoms selected from N, O, and S] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 2-furanylboronic acid. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -log<sub>10</sub>IC<sub>50</sub> values from 6.61 up to 7.61 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.




IT 849356-71-4P 849356-72-5P 849356-73-6P  
849356-74-7P 849356-75-8P 849356-76-9P  
849356-77-0P 849356-78-1P 849356-79-2P  
849356-80-5P 849356-81-6P 849356-82-7P  
849356-83-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)


RN 849356-71-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(2-furanyl)-2-[2-(4-methoxy-2-  
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-72-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(3-furanyl)-2-[2-(4-methoxy-2-  
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-73-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-  
pyridinyl)- (9CI) (CA INDEX NAME)




RN 849356-74-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-  
thienyl)- (9CI) (CA INDEX NAME)




RN 849356-75-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-  
thienyl)- (9CI) (CA INDEX NAME)




RN 849356-76-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(1H-indol-5-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-77-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(1H-benzimidazol-2-yl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-78-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-methyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 849356-79-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-3-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-80-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(2-benzofuranyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-81-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-benzo[b]thien-2-yl-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 849356-82-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 849356-83-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)




IT 608880-54-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 608880-54-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:300444 CAPLUS  
 DOCUMENT NUMBER: 142:373835  
 TITLE: Preparation of imidazopyridine derivatives as  
 inducible NO-synthase inhibitors  
 INVENTOR(S): Boer, Rainer; Ulrich, Wolf-Ruediger; Eltze, Manfred;  
 Marx, Degenhard; Graedler, Ulrich; Fuchss, Thomas  
 PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030768	A1	20050407	WO 2004-EP52370	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276012	A1	20050407	AU 2004-276012	20040930
CA 2540239	A1	20050407	CA 2004-2540239	20040930
EP 1675853	A1	20060705	EP 2004-787257	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856492	A	20061101	CN 2004-80027796	20040930
BR 2004015038	A	20061212	BR 2004-15038	20040930
JP 2007507463	T	20070329	JP 2006-530260	20040930
NO 2006001343	A	20060324	NO 2006-1343	20060324
MX 2006PA03347	A	20060608	MX 2006-PA3347	20060324
US 2007010549	A1	20070111	US 2006-573203	20060324
IN 2006MN00474	A	20070817	IN 2006-MN474	20060424
PRIORITY APPLN. INFO.:			EP 2003-22042	A 20031001
			WO 2004-EP52370	W 20040930
OTHER SOURCE(S):			CASREACT 142:373835; MARPAT 142:373835	
GI				



AB Title compds. I [R1 = H, alkyl; R2 = H, halo, OH, etc.; R3 = H, halo, alkyl, alkoxy; R4 = alkyl; R5 = alkyl] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible NO-synthase inhibitors. Thus, e.g., II was prepared via Wittig reaction of triphenyl-[1-(3H-imidazo[4,5-b]pyridin-2-yl)-propyl]-phosphonium chloride (preparation given) with 4-methoxypyridine-2-carboxaldehyde and subsequent hydrogenation. The activity of II towards inducible NO-synthase was evaluated in an inhibition assay and revealed a  $-\log IC_{50}$  value of 7.15 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.


IT 849346-44-7P 849346-45-8P 849346-46-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849346-44-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1-methylethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 849346-45-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[1-[(4-methoxy-2-pyridinyl)methyl]propyl]-, (9CI) (CA INDEX NAME)



RN 849346-46-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1,1-dimethylethyl]-  
(9CI) (CA INDEX NAME)




IT 849346-55-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849346-55-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)-1-methylethyl]-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777790 CAPLUS

DOCUMENT NUMBER: 139:292156

TITLE: Preparation of alkoxy pyridines as inducible nitric  
oxide synthase (iNOS) inhibitors

INVENTOR(S): Boer, Rainer; Marx, Degenhard; Eltze, Manfred; Klein,  
Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss,  
Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,				

SI, SK, TR

CA 2480385	A1	20031002	CA 2003-2480385	20030325
AU 2003226706	A1	20031008	AU 2003-226706	20030325
EP 1490366	A1	20041229	EP 2003-744851	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008785	A	20050111	BR 2003-8785	20030325
CN 1642955	A	20050720	CN 2003-806917	20030325
JP 2005525388	T	20050825	JP 2003-578361	20030325
NZ 535959	A	20060526	NZ 2003-535959	20030325
IN 2004MN00462	A	20050218	IN 2004-MN462	20040820
MX 2004PA09283	A	20050125	MX 2004-PA9283	20040923
US 2005171125	A1	20050804	US 2004-509396	20040924
US 7138399	B2	20061121		
ZA 2004007766	A	20060628	ZA 2004-7766	20040927
NO 2004004633	A	20041223	NO 2004-4633	20041027
PRIORITY APPLN. INFO.:			EP 2002-7049	A 20020327
OTHER SOURCE(S):			WO 2003-EP3076	W 20030325
GI			MARPAT 139:292156	




- AB Title compds. I [wherein R<sup>1</sup> = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC<sub>50</sub> (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).
- IT 608880-48-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-53-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-bromo-3H-imidazo[4,5-b]pyridine 608880-54-2P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine 608880-74-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-aminophenyl)-3H-imidazo[4,5-b]pyridine
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(inducible NO-synthase inhibitor; preparation of alkoxy pyridines as inducible NO-synthase inhibitors)


RN 608880-48-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-53-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-bromo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-54-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-iodo-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 608880-74-6 CAPLUS

CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



IT 608880-50-8P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-methyl-3H-imidazo[4,5-b]pyridine 608880-51-9P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 608880-52-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-5-methoxy-3H-imidazo[4,5-b]pyridine 608880-55-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-nitro-3H-imidazo[4,5-b]pyridine 608880-56-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-trifluoromethyl-3H-imidazo[4,5-b]pyridine 608880-57-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-phenyl-3H-imidazo[4,5-b]pyridine 608880-58-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-methyl-3H-imidazo[4,5-b]pyridine 608880-59-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(2-methylpropyl)-3H-imidazo[4,5-b]pyridine 608880-60-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-cyclohexylmethyl-3H-imidazo[4,5-b]pyridine 608880-61-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(2-phenylethyl)-3H-imidazo[4,5-




b]pyridine 608880-62-2P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-dichlorophenyl)-3H-imidazo[4,5-b]pyridine 608880-63-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-bromophenyl)-3H-imidazo[4,5-b]pyridine 608880-64-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-bromobenzyl)-3H-imidazo[4,5-b]pyridine 608880-65-5P, 7-(2-Methoxyethoxy)-2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-66-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2-phenylethoxy)-3H-imidazo[4,5-b]pyridine 608880-67-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2,2,2-trifluoroethoxy)-3H-imidazo[4,5-b]pyridine 608880-68-8P, 7-Hydroxy-2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-69-9P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-(2-p-tolyloethyl)-3H-imidazo[4,5-b]pyridine 608880-70-2P, 2,7-Bis[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-71-3P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-7-[2-(2-pyridyl)ethyl]-3H-imidazo[4,5-b]pyridine 608880-72-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-p-tolyl-3H-imidazo[4,5-b]pyridine 608880-73-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine 608880-75-7P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-hydroxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-76-8P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-[4-(N,N-dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridine 608880-77-9P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-trifluoromethylphenyl)-3H-imidazo[4,5-b]pyridine 608880-78-0P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(3,4-dimethoxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-79-1P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-benzyloxyphenyl)-3H-imidazo[4,5-b]pyridine 608880-80-4P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-benzyloxy-3-fluorophenyl)-3H-imidazo[4,5-b]pyridine 608880-81-5P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(4-cyanophenyl)-3H-imidazo[4,5-b]pyridine 608880-82-6P, 2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine-6-carboxylic acid methyl ester 608880-83-7P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]acetamide 608880-84-8P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]benzenesulfonamide 608880-85-9P, 2-[2-(4-Methoxy-1-oxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inducible NO-synthase inhibitor; preparation of alkoxypyridines as inducible NO-synthase inhibitors)


RN 608880-50-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-methyl- (9CI) (CA INDEX NAME)




RN 608880-51-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-5,7-dimethyl- (9CI) (CA INDEX NAME)




RN 608880-52-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[2-(4-methoxy-2-pyridinyl)ethyl]-  
(9CI) (CA INDEX NAME)




RN 608880-55-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-nitro-  
(9CI) (CA INDEX NAME)




RN 608880-56-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-  
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 608880-57-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-phenyl-  
(9CI) (CA INDEX NAME)




RN 608880-58-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-methyl-  
(9CI) (CA INDEX NAME)




RN 608880-59-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 608880-60-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(cyclohexylmethyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-61-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 608880-62-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(3,4-dichlorophenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-63-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(4-bromophenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-64-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-[(4-bromophenyl)methyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-65-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 7-(2-methoxyethoxy)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-66-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-(2-phenylethoxy)- (9CI) (CA INDEX NAME)




RN 608880-67-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 608880-68-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-7-ol, 2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-69-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-70-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2,7-bis[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-71-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-7-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-72-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 608880-73-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 608880-75-7 CAPLUS

CN Phenol, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 608880-76-8 CAPLUS

CN Benzenamine, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 608880-77-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 608880-78-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-(3,4-dimethoxyphenyl)-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-79-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-6-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 608880-80-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 6-[3-fluoro-4-(phenylmethoxy)phenyl]-2-[2-(4-methoxy-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 608880-81-5 CAPLUS

CN Benzonitrile, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




RN 608880-82-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-6-carboxylic acid, 2-[2-(4-methoxy-2-pyridinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 608880-83-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 608880-84-8 CAPLUS

CN Benzenesulfonamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 608880-85-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[2-(4-methoxy-1-oxido-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:37:29 ON 12 OCT 2007)

FILE 'REGISTRY' ENTERED AT 07:37:34 ON 12 OCT 2007

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 133 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:38:01 ON 12 OCT 2007

L4 7 S L3 FULL



=> log y  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
39.71	212.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-5.46	-5.46

STN INTERNATIONAL LOGOFF AT 07:41:44 ON 12 OCT 2007